EyePoint Pharmaceuticals (EYPT) Stock Forecast & Price Target

$7.95

-0.04 (-0.50%)

(As of 02:48 PM ET)

EyePoint Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 8 Analyst Ratings

Sell
0

Hold
0

Buy
8

Based on 8 Wall Street analysts who have issued ratings for EyePoint Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Buy." Out of the 8 analysts, 8 have given a buy rating for EYPT.

Consensus Price Target

$30.57
288.46% Upside

According to the 8 analysts' twelve-month price targets for EyePoint Pharmaceuticals, the average price target is $30.57. The highest price target for EYPT is $44.00, while the lowest price target for EYPT is $15.00. The average price target represents a forecasted upside of 288.46% from the current price of $7.95.

Get the Latest News and Ratings for EYPT and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for EyePoint Pharmaceuticals and its competitors.

EYPT Analyst Ratings Over Time

Type	Current Forecast 10/2/23 to 10/1/24	1 Month Ago 9/2/23 to 9/1/24	3 Months Ago 7/4/23 to 7/3/24	1 Year Ago 10/2/22 to 10/2/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	8 Buy rating(s)	8 Buy rating(s)	7 Buy rating(s)	5 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$30.57	$30.63	$33.29	$33.00
Forecasted Upside	288.46% Upside	242.18% Upside	286.15% Upside	323.08% Upside
Consensus Rating	Buy	Buy	Buy	Buy

$20 = Ounce of Gold? (Ad)

I've discovered a way to get exposure to MORE than an ounce of gold... for under $20. It's not bullion. It's not ETFs. And it's certainly not crypto.

Click here to find out why this is my favorite gold stock.

EYPT Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

EYPT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

EyePoint Pharmaceuticals Stock vs. The Competition

Type	EyePoint Pharmaceuticals	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.78	2.50
Consensus Rating	Buy	Moderate Buy	Hold
Predicted Upside	282.62% Upside	823.06% Upside	6.15% Upside
News Sentiment Rating	Very Positive News See Recent EYPT News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
8/28/2024	Jefferies Financial Group 2 of 5 stars		Initiated Coverage	Buy	$15.00	+65.02%
8/13/2024	JPMorgan Chase & Co. 3 of 5 stars		Lower Target	Overweight ➝ Overweight	$32.00 ➝ $29.00	+246.89%
6/28/2024	Chardan Capital 2 of 5 stars		Reiterated Rating	Buy ➝ Buy	$28.00 ➝ $28.00	+220.00%
6/27/2024	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00	+266.30%
6/20/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight
5/8/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$46.00 ➝ $38.00	+220.13%
Get the Latest News and Ratings for EYPT and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for EyePoint Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.
5/7/2024	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$39.00 ➝ $30.00	+167.86%
2/16/2024	Capital One Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	T. Chiang Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight
11/11/2022	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy	$60.00 ➝ $52.00	+1,015.88%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 03:15 PM ET.

EYPT Forecast - Frequently Asked Questions

: According to the research reports of 8 Wall Street equities research analysts, the average twelve-month stock price forecast for EyePoint Pharmaceuticals is $30.57, with a high forecast of $44.00 and a low forecast of $15.00.
: 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for EyePoint Pharmaceuticals in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" EYPT shares.
: According to analysts, EyePoint Pharmaceuticals's stock has a predicted upside of 284.55% based on their 12-month stock forecasts.
: EyePoint Pharmaceuticals has been rated by research analysts at Jefferies Financial Group, and JPMorgan Chase & Co. in the past 90 days.
: Analysts like EyePoint Pharmaceuticals more than other "medical" companies. The consensus rating for EyePoint Pharmaceuticals is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how EYPT compares to other companies.